Sign In
Buy VIR
$8.77
+0.0300 (+0.343%)
At Close: Jun 03, 2026
Vir Biotechnology, Inc. (VIR) Q1 Earnings and Revenues Beat Estimates
06:48pm, Thursday, 05'th May 2022
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 19.94% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More
07:19pm, Wednesday, 04'th May 2022 Zacks Investment Research
Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.
Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More
04:33pm, Wednesday, 04'th May 2022
Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.
These stocks soared during the pandemic, and then crashed. Ten are now expected to double in price.
11:00am, Wednesday, 04'th May 2022 MarketWatch
The group rose at least 300% in the pandemic before crashing 70% or more.
Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline
05:26pm, Monday, 02'nd May 2022 Benzinga
Recently, Vir Biotechnology Inc (NASDAQ: VIR) announced updates on its expansive hepatitis portfolio, including VIR-2218 which is part of a collaboration with Alnylam Pharmaceuticals Inc (NASDAQ:
Vir Biotechnology: Expanded Hepatitis Pipeline And COVID-19 Revenue Expected
03:42pm, Monday, 02'nd May 2022
Vir Biotechnology had obtained about $917.2 million of sotrovimab collaboration revenue in 2021; Expects about $1.1 billion in revenues with all doses delivered by 1st half of 2022. About 95% of patie
Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline
01:41pm, Monday, 02'nd May 2022
Recently, Vir Biotechnology Inc (NASDAQ: VIR) announced updates on its expansive hepatitis portfolio, including VIR-2218 which is part of a collaboration with Alnylam Pharmaceuticals Inc (NASDAQ:
Vir Biotechnology, Inc. (VIR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
07:02pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can a decades-old antidepressant keep COVID-19 patients out of the hospital?
01:00pm, Thursday, 28'th Apr 2022 MarketWatch
It's one of several generic drugs that's being tested as a way to treat the virus.
Glaxo's (GSK) Q1 Earnings Top, Xevudy Adds $1.7B in Sales
03:10pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Glaxo's (GSK) revenues benefit from the strong growth in sales across all categories along with additional sales from its COVID-19 antibody drug, Xevudy.
Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day
12:39pm, Wednesday, 27'th Apr 2022 GlobeNewswire Inc.
– Strategic clinical program for hepatitis B and D with potential for multiple value drivers in 2022 –
Glaxo (GSK) to Report Q1 Earnings: What's in the Cards?
01:02pm, Monday, 25'th Apr 2022 Zacks Investment Research
Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven first-quarter sales. The performance of vaccines during Q1 remains to be seen.
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022
08:05pm, Thursday, 21'st Apr 2022 GlobeNewswire Inc.
SAN FRANCISCO, April 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022
04:05pm, Thursday, 21'st Apr 2022
SAN FRANCISCO, April 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter e
Regeneron (REGN) REGEN-COV BLA Review Extended by 3 Months
04:12pm, Monday, 18'th Apr 2022 Zacks Investment Research
Regeneron (REGN) biologics license application for antibody cocktail REGEN-COV (casirivimab and imdevimab) gets a three-month FDA extension.
